search
Back to results

Treatment of Incontinence Associated Dermatitis - Automated (TRIAD-A)

Primary Purpose

Incontinence, Urinary, Dermatitis, Incontinence, Fecal

Status
Unknown status
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Wellness toileting system
Sponsored by
SchwabCare
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Incontinence, Urinary

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Ability to give informed consent.
  • Active functional urinary or fecal incontinence
  • Kennedy Scale Grade >2 with active incontinence associated dermatitis
  • Willingness to have device installed in home/care center

Exclusion Criteria:

  • Active perineal infection
  • Prior pelvic radiation
  • Perineal surgery within the prior 6 months
  • Known allergy or sensitivity to applied agents
  • Treatment for dermatitis within the prior 2 weeks.
  • Pre-existing pressure ulcer stage 2-4
  • Weight exceeding 300 pounds
  • Known allergy or hypersensitivity to cleanser or zinc oxide barrier spray
  • Home bathroom needs excessive upgrades, or needs ownership authorization

Sites / Locations

  • Skyline UrologyRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Wellness toileting system

Arm Description

This group will use the wellness toileting system for their perineal hygiene and treatment of dermatitis

Outcomes

Primary Outcome Measures

Treatment of dermatitis
Improvement in the Kennedy Score for Dermatitis

Secondary Outcome Measures

Prevention of recurrent dermatitis
prevention of recurrent dermatitis by clinical criteria
Improvement in quality of life
Assessed by visual analog scale derived from quality of life in incontinence scale

Full Information

First Posted
February 6, 2017
Last Updated
May 29, 2018
Sponsor
SchwabCare
search

1. Study Identification

Unique Protocol Identification Number
NCT03046810
Brief Title
Treatment of Incontinence Associated Dermatitis - Automated
Acronym
TRIAD-A
Official Title
Treatment of Incontinence Associated Dermatitis - Automated
Study Type
Interventional

2. Study Status

Record Verification Date
May 2018
Overall Recruitment Status
Unknown status
Study Start Date
April 1, 2017 (Actual)
Primary Completion Date
July 2019 (Anticipated)
Study Completion Date
September 2019 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
SchwabCare

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Incontinence and the skin irritation (dermatitis) associated with it are common problems. Treatment of dermatitis is effective, but requires effective cleaning and application of a barrier substance to prevent further contact between urine or feces and the skin. Water based cleansing with the addition of a pH balanced cleanser is more effective than standard abrasive cleansing with paper or a cloth, and is better tolerated by those with skin irritation. Zinc oxide based barriers effectively promote healing and prevent further skin damage. Spray forms are less cumbersome and generally preferred, but are difficult to for the patient to apply independently given the challenge of accessing the perineum. 40 patients, recruited from 3 specialty pelvic floor centers and 1 assisted living center will be provided a device that cleans, dries, and applies zinc oxide barrier spray with each use of the toilet. Dermatitis will be evaluated at the beginning of the study, and at weeks 1, 2 and 6 by medical staff using a standard scale (The Kennedy Scale).Quality of life will be measured using a visual analog scale derived from the quality of life in incontinence scale. The investigators hypothesize that the device will 1) effectively treat incontinence associated dermatitis, 2) prevent recurrence, and 3) be preferred over standard treatment.
Detailed Description
Incontinence and incontinence associated dermatitis (IAD) are common problems. A recent CDC study noted that up to 50% of noninstitutionalized patients aged 65 and older experienced episodes of incontinence at least monthly, and that 40% of those with incontinence develop secondary IAD The treatment of IAD is focused on effective cleaning and prevention of further exposure to irritant liquids and solids through barrier creams. Enzymatic washes have proven efficacy over soap and water, and zinc oxide is the standard of care for barrier function. Combined, effective cleansing and barrier use treats IAD in as little as 6 days, and effectively prevents recurrent skin damage. In one study, an effective preventive regimen of regularly applied skin therapy reduced the incidence of IAD in an at risk population from 25% to 5%. The combination of enzymatic skin cleanser and barrier protection is the standard of care for maintenance of skin integrity in patients with chronic urinary and fecal incontinence. Adherence to prescribed regimens is a major barrier to regular use of substances applied to the perineum. Difficulty in accessing the perineum make adherence challenging to those with both full and limited mobility, often requiring assistance from a caregiver. The associated loss of independence and dignity are major detriments to quality of life. Novel formulations of zinc oxide, using aerosol based spray application, facilitate use and improve patient acceptance. In a 2014 nursing home based industry study, spray based zinc oxide was preferred by 80% of patients and caregivers, and improved treatment and prevention of IAD in 70% of the study participants. Adequate cleansing and drying prior to the application of barrier products is key to effective prevention of skin breakdown. Water-based cleaning of the perineum after toileting has been demonstrated to improve hygiene over standard mechanical, paper-based cleansing, especially in those with limited mobility or incontinence. Evidence further demonstrates that the addition of pH balanced cleansers, applied without mechanical abrasion from cloths or wipes, advances hygiene and minimizes risk of secondary infection. Study Aims The aims of this study are to evaluate the efficacy of an automated delivery system for cleansing the perineum, and applying zinc oxide barrier spray to effectively treat and prevent incontinence associated dermatitis in a population with active or recurrent IAD. Secondary aims will be to assess preference for the automated delivery system over standard wash and manually applied barrier sprays.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Incontinence, Urinary, Dermatitis, Incontinence, Fecal

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
40 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Wellness toileting system
Arm Type
Experimental
Arm Description
This group will use the wellness toileting system for their perineal hygiene and treatment of dermatitis
Intervention Type
Device
Intervention Name(s)
Wellness toileting system
Other Intervention Name(s)
SchwabCare Wellness Toileting System
Intervention Description
This group will use the wash, dry, cleanse, and apply zinc oxide barrier spray routinely for all toileting.
Primary Outcome Measure Information:
Title
Treatment of dermatitis
Description
Improvement in the Kennedy Score for Dermatitis
Time Frame
6 weeks
Secondary Outcome Measure Information:
Title
Prevention of recurrent dermatitis
Description
prevention of recurrent dermatitis by clinical criteria
Time Frame
12 weeks
Title
Improvement in quality of life
Description
Assessed by visual analog scale derived from quality of life in incontinence scale
Time Frame
12 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Ability to give informed consent. Active functional urinary or fecal incontinence Kennedy Scale Grade >2 with active incontinence associated dermatitis Willingness to have device installed in home/care center Exclusion Criteria: Active perineal infection Prior pelvic radiation Perineal surgery within the prior 6 months Known allergy or sensitivity to applied agents Treatment for dermatitis within the prior 2 weeks. Pre-existing pressure ulcer stage 2-4 Weight exceeding 300 pounds Known allergy or hypersensitivity to cleanser or zinc oxide barrier spray Home bathroom needs excessive upgrades, or needs ownership authorization
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Jacqueline Silvia
Phone
+1 (855) 239-2106
Email
jsilvia@schwabcare.com
First Name & Middle Initial & Last Name or Official Title & Degree
Richard S Tilson, MD MPH
Phone
(978) 459-6737
Email
mtilson2@lowellgi.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Richard S Tilson, MD MPH
Organizational Affiliation
Director of Clinical Investigation
Official's Role
Principal Investigator
Facility Information:
Facility Name
Skyline Urology
City
Torrance
State/Province
California
ZIP/Postal Code
90505
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jacqueline Silvia

12. IPD Sharing Statement

Plan to Share IPD
No
IPD Sharing Plan Description
No plan to share individual participant data at this time

Learn more about this trial

Treatment of Incontinence Associated Dermatitis - Automated

We'll reach out to this number within 24 hrs